Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy

OSLO, Norway & SEOUL, Korea--(BUSINESS WIRE)--The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency (’Statens Legemiddelverk’) to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, ”We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs. The main reason for choosing GV1001 for this combination study is that it is a peptide anti-cancer vaccine in Phase III trial, directed against the telomerase enzyme, and is one of the best documented therapeutic cancer vaccine currently in development. The telomerase-target for therapeutic vaccination is universally expressed in tumours, making a GV1001/LTX-315 combination treatment potentially useful in a wide range of cancer types.” The excellence of the GV1001 vaccine has previously been proven in studies at the Cancer Centre of Karolinska Institute in Stockholm, Sweden, Radium Hospital Medical Center in Oslo, Norway as well as University of Liverpool, UK. KAEL-GemVax CEO, Jay Sangjae Kim, also commented on LTX-315 saying that, ”In preclinical models, LTX-315 causes release of cellular ’danger’ signals that trigger activation of the innate immune system. This creates an optimal environment in which to generate strong immune responses towards peptide vaccines.”

Back to news